Jasper Therapeutics, Inc. JSPR
Price alert —
Sign in to get a one-time email the moment JSPR crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · JSPR
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-12-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-09-30 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-06-30 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-03-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare JSPR vs peers
Line JSPR up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with JSPR
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 19 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-14 | -0.38 | -0.54 | +30.1% | -11.4% |
| 2026-03-30 | -0.54 | -0.82 | +33.8% | -2.7% |
| 2025-11-10 | -1.13 | -1.21 | +7.0% | -4.5% |
| 2025-08-13 | -1.74 | -1.33 | -31.2% | +2.0% |
| 2025-05-12 | -1.41 | -1.48 | +4.5% | +1.7% |
| 2025-02-27 | -1.62 | -1.23 | -31.9% | +4.6% |
| 2024-11-07 | -1.24 | -1.08 | -15.4% | +8.1% |
| 2024-08-13 | -0.97 | -1.12 | +13.3% | -4.6% |
| 2024-05-14 | -1.03 | -1.18 | +12.9% | +3.2% |
| 2024-03-04 | -1.50 | -1.57 | +4.2% | +11.6% |
| 2023-11-09 | -1.63 | -1.50 | -8.6% | -6.4% |
| 2023-08-11 | -1.51 | -1.47 | -3.0% | -4.3% |
| 2023-05-12 | -1.47 | -1.50 | +2.3% | -0.6% |
| 2023-03-08 | -3.67 | -4.00 | +8.3% | -7.0% |
| 2022-11-10 | -3.20 | -3.70 | +13.5% | +1.5% |
| 2022-08-12 | -2.45 | -3.60 | +31.8% | -7.1% |
| 2022-05-12 | -3.54 | -3.40 | -4.1% | +2.0% |
| 2022-03-18 | -2.10 | -3.67 | +42.7% | +1.1% |
| 2021-11-12 | -2.67 | -2.70 | +1.2% | +4.2% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| JSPR ★ | $0B | — | -0.3 | — | -0.2 | 7.3 | — | — | — | -143.05% |
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 45.6%
| Holder | Shares | % out |
|---|---|---|
| Velan Capital Investment Management | 2,668,395 | 9.53% |
| Millennium Management Llc | 1,617,531 | 5.77% |
| Acorn Capital Advisors, LLC | 1,411,492 | 5.04% |
| Kingdon Capital Management LLC | 1,352,106 | 4.83% |
| Morgan Stanley | 1,333,420 | 4.76% |
| Vanguard Capital Management LLC | 1,172,597 | 4.19% |
| Rock Springs Capital Management, LP | 1,100,726 | 3.93% |
| Carlyle Group Inc. | 1,066,189 | 3.81% |
| Boothbay Fund Management, LLC | 582,751 | 2.08% |
| Lion Point Capital, LP | 465,000 | 1.66% |
Insider activity · 90d
No insider trades for JSPR in last 90d.
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 8-K | 2026-07-17 | CURRENT REPORT | view · |
| 8-K | 2026-07-16 | CURRENT REPORT | view · |
| DEF 14A | 2026-06-15 | PROXY STATEMENT | view · |
| 8-K | 2026-06-09 | CURRENT REPORT | view · |
| 8-K | 2026-06-01 | CURRENT REPORT | view · |
| 8-K | 2026-05-21 | CURRENT REPORT | view · |
| 10-Q | 2026-05-14 | QUARTERLY REPORT | view · |
| 8-K | 2026-05-14 | CURRENT REPORT | view · |
| 8-K | 2026-03-30 | CURRENT REPORT | view · |
| 10-K | 2026-03-30 | ANNUAL REPORT | view · |
| 4 | 2026-02-10 | Insider transaction (Form 4) | view · |
| 8-K | 2026-01-08 | CURRENT REPORT | view · |
| 8-K | 2026-01-07 | CURRENT REPORT | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 8-K | 2025-12-02 | CURRENT REPORT | view · |
| 10-Q | 2025-11-10 | QUARTERLY REPORT | view · |
| 8-K | 2025-11-10 | CURRENT REPORT | view · |
| 4 | 2025-09-24 | Insider transaction (Form 4) | view · |
| 4 | 2025-09-24 | Insider transaction (Form 4) | view · |
| 4 | 2025-09-24 | Insider transaction (Form 4) | view · |
| 4 | 2025-09-24 | Insider transaction (Form 4) | view · |
| 8-K | 2025-09-19 | CURRENT REPORT | view · |
| 8-K | 2025-08-13 | CURRENT REPORT | view · |
| 10-Q | 2025-08-13 | QUARTERLY REPORT | view · |
| 8-K | 2025-07-09 | CURRENT REPORT | view · |
| 8-K | 2025-07-07 | CURRENT REPORT | view · |
| 4 | 2025-07-03 | Insider transaction (Form 4) | view · |
| 4 | 2025-07-03 | Insider transaction (Form 4) | view · |
| 4 | 2025-07-03 | Insider transaction (Form 4) | view · |
| 4 | 2025-07-03 | Insider transaction (Form 4) | view · |
| 4 | 2025-07-03 | Insider transaction (Form 4) | view · |
| 4 | 2025-07-03 | Insider transaction (Form 4) | view · |
| 4 | 2025-07-03 | Insider transaction (Form 4) | view · |
| 8-K | 2025-07-03 | CURRENT REPORT | view · |
| 8-K | 2025-06-16 | CURRENT REPORT | view · |
| 4 | 2025-06-06 | Insider transaction (Form 4) | view · |
| 4 | 2025-06-06 | Insider transaction (Form 4) | view · |
| 4 | 2025-06-06 | Insider transaction (Form 4) | view · |
| 4 | 2025-06-06 | Insider transaction (Form 4) | view · |
| DEF 14A | 2025-05-19 | DEFINITIVE PROXY STATEMENT | view · |
| 8-K | 2025-05-12 | CURRENT REPORT | view · |
| 10-Q | 2025-05-12 | QUARTERLY REPORT | view · |
| 8-K | 2025-03-19 | CURRENT REPORT | view · |
| 10-K | 2025-02-28 | ANNUAL REPORT | view · |
| 8-K | 2025-02-27 | CURRENT REPORT | view · |
| 4 | 2025-02-18 | Insider transaction (Form 4) | view · |
| 4 | 2025-02-18 | Insider transaction (Form 4) | view · |
| 4 | 2025-02-18 | Insider transaction (Form 4) | view · |
| 4 | 2025-02-18 | Insider transaction (Form 4) | view · |
| 8-K | 2025-01-08 | CURRENT REPORT | view · |
| 4 | 2024-12-12 | Insider transaction (Form 4) | view · |
| 8-K | 2024-11-07 | CURRENT REPORT | view · |
| 10-Q | 2024-11-07 | QUARTERLY REPORT | view · |
| 8-K | 2024-10-15 | CURRENT REPORT | view · |
| 4 | 2024-09-12 | Insider transaction (Form 4) | view · |
| 10-Q | 2024-08-13 | QUARTERLY REPORT | view · |
| 4 | 2024-06-20 | Insider transaction (Form 4) | view · |
| 8-K | 2024-06-20 | CURRENT REPORT | view · |
About JSPR
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California.
Options picks · JSPR
ITM + OTM ideas from the latest scanLoading…
Congress trades · JSPR
STOCK Act disclosuresLoading…
SEC filings & insiders · JSPR
EDGAR · liveLoading…
Holders · JSPR
Institutions & insider activityLoading…